Allergan PLC (NYSE:AGN) was up 1.9% during mid-day trading on Wednesday . The company traded as high as $246.16 and last traded at $244.18, with a volume of 2,226,613 shares trading hands. The stock had previously closed at $239.70.

A number of equities research analysts recently issued reports on AGN shares. Leerink Swann reissued an “outperform” rating on shares of Allergan PLC in a research report on Wednesday, March 16th. Canaccord Genuity reissued a “buy” rating and issued a $320.00 target price (down previously from $340.00) on shares of Allergan PLC in a research report on Thursday, March 31st. Nomura Holdings Inc. reissued a “buy” rating and issued a $330.00 target price (down previously from $350.00) on shares of Allergan PLC in a research report on Tuesday, April 5th. Cowen and Company reissued a “buy” rating on shares of Allergan PLC in a research report on Tuesday, April 5th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $354.00 target price on shares of Allergan PLC in a research report on Tuesday, April 5th. Seven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $307.78.

The company has a 50-day moving average price of $236.95 and a 200-day moving average price of $258.33. The firm has a market capitalization of $95.40 billion and a P/E ratio of 21.58.

Allergan PLC (NYSE:AGN) last issued its quarterly earnings results on Tuesday, May 10th. The company reported $3.04 EPS for the quarter, beating the Zacks’ consensus estimate of $3.03 by $0.01. The business had revenue of $3.80 billion for the quarter, compared to analysts’ expectations of $3.97 billion. The firm’s revenue for the quarter was up 48.1% compared to the same quarter last year. Equities analysts expect that Allergan PLC will post $14.20 earnings per share for the current fiscal year.

In other Allergan PLC news, CFO Maria Teresa Hilado purchased 661 shares of the firm’s stock in a transaction that occurred on Thursday, June 2nd. The stock was bought at an average cost of $241.57 per share, with a total value of $159,677.77. Following the completion of the transaction, the chief financial officer now owns 11,957 shares of the company’s stock, valued at approximately $2,888,452.49. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nesli Basgoz sold 459 shares of the stock in a transaction that occurred on Wednesday, May 11th. The shares were sold at an average price of $225.10, for a total value of $103,320.90. Following the sale, the director now directly owns 5,242 shares of the company’s stock, valued at $1,179,974.20. The disclosure for this sale can be found here.

Several hedge funds have modified their holdings of the stock. Moors & Cabot Inc. increased its stake in shares of Allergan PLC by 149.3% in the fourth quarter. Moors & Cabot Inc. now owns 3,498 shares of the company’s stock worth $1,095,000 after buying an additional 2,095 shares during the last quarter. LS Investment Advisors LLC raised its position in shares of Allergan PLC by 45.7% in the fourth quarter. LS Investment Advisors LLC now owns 3,513 shares of the company’s stock valued at $1,098,000 after buying an additional 1,102 shares during the period. Ironsides Asset Advisors LLC purchased a new position in shares of Allergan PLC during the fourth quarter valued at $1,112,000. Northeast Financial Consultants Inc raised its position in shares of Allergan PLC by 12.6% in the fourth quarter. Northeast Financial Consultants Inc now owns 3,805 shares of the company’s stock valued at $1,190,000 after buying an additional 425 shares during the period. Finally, Private Advisor Group LLC raised its position in shares of Allergan PLC by 18.5% in the fourth quarter. Private Advisor Group LLC now owns 4,333 shares of the company’s stock valued at $1,354,000 after buying an additional 676 shares during the period.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.